RxDoctor Payments DataLook up a doctor →

Jie Yang

Hematology & Oncology · Norwich, CTNPI 1386719060

Payments from drug & device makers

$757,929in general payments, 2019–2025

Across 992 payments — averaging $764.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$725K
  • Chiesi USA, Inc.$13K
  • Genentech, Inc.$3K
  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • plus $12K from 54 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$500

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis77$725,423
Chiesi USA, Inc.11$12,700
Genentech, Inc.5$3,330
Johnson & Johnson(2 entities)97$1,686
AstraZeneca(2 entities)71$1,283
Pfizer70$1,052
Bayer39$862
Sanofi40$690
Rigel Pharmaceuticals, Inc.35$642
Incyte Corporation40$621
Astellas Pharma US Inc37$617
Merck36$598
Bristol Myers Squibb27$557
Gilead(2 entities)22$447
Genentech USA, Inc.23$407
Eisai Inc.20$399
Seagen Inc.21$398
Lilly USA, LLC22$396
AbbVie18$357
Exelixis Inc.18$329
Ipsen Biopharmaceuticals, Inc11$297
Takeda Pharmaceuticals U.S.A., Inc.15$294
Amgen15$274
E.r. Squibb & Sons, L.L.C.15$259
GSK12$252
Jazz Pharmaceuticals Inc.16$239
Epizyme, Inc.8$197
Array Biopharma Inc10$193
ADC Therapeutics America, Inc.8$191
Blueprint Medicines Corporation7$183
Mirati Therapeutics, Inc.10$175
Pharmacyclics LLC, An Abbvie Company8$175
Karyopharm Therapeutics Inc.10$168
Regeneron Healthcare Solutions, Inc.8$167
Sobi, Inc9$162
Daiichi Sankyo Inc.10$159
Sumitomo Pharma America, Inc.6$135
Pharmaessentia USA Corporation5$110
Geron Corporation4$102
AVEO Pharmaceuticals, Inc.5$101
EMD Serono, Inc.5$95
Stemline Therapeutics Inc.5$93
Pharmacosmos Therapeutics Inc.4$90
Coherus Oncology, Inc.3$68
AMAG Pharmaceuticals, Inc.5$67
Taiho Oncology, Inc.4$64
Beone Medicines USA, Inc.3$61
Morphosys, US Inc.4$57
Servier Pharmaceuticals LLC2$50
Beigene USA, Inc.3$47
Dova Pharmaceuticals3$46
Myriad Genetic Laboratories, Inc.3$46
Iovance Biotherapeutics, Inc.2$45
Acrotech Biopharma Inc.2$40
Sun Pharmaceutical Industries Inc.2$35
Boehringer Ingelheim1$32
Tersera Therapeutics LLC2$31
Dendreon Pharmaceuticals LLC1$26
Verastem, Inc.1$24
CSL Behring1$23

How this compares

$757,929 in reported general payments places this provider in the 85th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$2,683,816
Medicare patients
650
Services billed
130,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Norwich

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →